SCHEMBL5359701

SCHEMBL5359701

NC(=O)COC(Oc1ccc(S(N)(=O)=O)cc1)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
CA2 P00918 13/20 0.41
CA1 P00915 12/20 0.41
CA9 Q16790 12/20 0.41
CA12 O43570 10/20 0.41
CA7 P43166 8/20 0.41
CA4 P22748 3/20 0.41
CA14 Q9ULX7 2/20 0.41
CA3 P07451 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SOS1 Q07889 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365096 0.87 ALDH1A1 (0.36) ALDH1A1CA2CA1CA9CA12
SCHEMBL5359271 0.73 MAPK1 (0.47) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL11519686 0.67 SMN1; SMN2 (0.56) ALDH1A1HTTCA2CA1CA9
SCHEMBL5334789 0.67 ALDH1A1 (0.59) ALDH1A1HTTCA2CA1CA9
SCHEMBL20567459 0.67 ALDH1A1 (0.59) ALDH1A1HTTCA2CA1CA9
SCHEMBL189284 0.67 ALDH1A1 (0.59) ALDH1A1HTTCA2CA1CA9
SCHEMBL21556036 0.66 CA2 (0.59) ALDH1A1HTTCA2CA1CA9
SCHEMBL3576066 0.66 ALDH1A1 (0.73) ALDH1A1HTTCA2CA1CA9
SCHEMBL21556165 0.65 CA2 (0.58) ALDH1A1HTTCA2CA1CA9
SCHEMBL21556105 0.65 CA2 (0.58) ALDH1A1HTTCA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
EP-1644352-A1 PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS Allergan, Inc. (US) 2006-04-12 EP disclosed
WO-2005016917-A1 PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS ALLERGAN, INC. (US) 2005-02-24 WO disclosed
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors SI, ATP6AP1, HRH2 ALDH1A1 1650/4885HTT 2706/4885CA2 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.